Although high‐dose IL‐2 remains a good treatment option for a subgroup of metastatic renal cancer and melanoma patients, its more widespread use has been limited by its toxicity, relatively short half‐life, and variability in patient responses.104. The gene discussed is IL2; the disease is melanoma.